This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
CAR-T! The living drug that saved Dr. Koffman’s life. We are gearing up to open the book on this revolutionary, potentially curative treatment, that we hope will soon be approved for CLL.
CLL Society Webinar “The Future of CAR-T Therapy: Can CAR-T Cure CLL?”
Join CLL Society on Tuesday, November 17 at 2 PM ET for a webinar with Dr. Joseph A. Fraietta from U Penn. You would be hard-pressed to find a researcher with more personal experience and clinical expertise in CAR-T and other cellular therapies than Dr. Fraietta. Don’t miss the excitement! Come to learn about the latest CAR-T research and to ask your questions of one of CAR-T’s most innovative pioneers. Learn more and register here.
Some fun and informative reading
So, speaking of books: Let’s revisit “The Amazing Transformation of CAR-T!” Put your feet up and enjoy turning the virtual pages of this charming comic. Consider it your Primer in CAR-T, lovingly drawn by our son, William, not having any idea that his father’s life would one-day be saved by this experimental therapy.
Please SMILE on the CLL Society! Today is AMAZON PRIME DAY! Remember to log into your Amazon account at Smile.Amazon.com and select the CLL Society as your designated charity. It is a big help to us.
Share Your Story!
Do you have personal experience with CAR-T? Would you like to share your story in our upcoming Q4 2020 CAR-T Special Edition Tribune? It is an extraordinary kindness to share both the easy and the rough parts of your journey with patients considering CAR-T. If you are one of the very few CLL patients who have experienced CAR-T and are interested in writing for us, please drop us an email at Support@cllsociety.org with the subject line “A CAR-T Story” to get the ball rolling. One of our staff will get back to you shortly. Thanks!
Conference Coverage ASH 2019
CLL is a smart cancer, but we are smarter. Dr. Tam at ASH 2019 talks about the outstanding results of the CAPTIVATE trial combining two great drugs, namely ibrutinib and venetoclax.
MRD in Clinical Practice
If you want to take a deeper dive into the evolving role of testing for MRD, or measurable residual disease, in managing CLL, see Dr. Koffman’s discussion of Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
Please Support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
Thank you and stay safe!
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.